![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2018
Sebio, A.; Stintzing, S.; Heinemann, V.; Sunakawa, Y.; Zhang, W.; Ichikawa, W.; Tsuji, A.; Takahashi, T.; Parek, A.; Yang, D.; Cao, S.; Ning, Y.; Stremitzer, S.; Matsusaka, S.; Okazaki, S.; Barzi, A.; Berger, M. D. und Lenz, H-J
(2018):
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
In: Pharmacogenomics Journal, Bd. 18, Nr. 1: S. 43-48
2017
Berger, M. D.; Stintzing, S.; Heinemann, V.; Yang, D.; Cao, S.; Sunakawa, Y.; Ning, Y.; Matsusaka, S.; Okazaki, S.; Miyamoto, Y.; Suenaga, M.; Schirripa, M.; Soni, S.; Zhang, W.; Falcone, A.; Loupakis, F. und Lenz, H.-J.
(2017):
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2780-2785
2016
Sebio, A.; Matsusaka, S.; Zhang, W.; Yang, D.; Ning, Y.; Stremitzer, S.; Stintzing, S.; Sunakawa, Y.; Yamauchi, S.; Fujimoto, Y.; Ueno, M. und Lenz, H-J
(2016):
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
In: Pharmacogenomics Journal, Bd. 16, Nr. 4: S. 312-319